Conference Call October 20, 8:45am EST QUEENSBURY, N.Y.–(BUSINESS WIRE)–Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September 30, 2025, and updated 2025 full-year revenue guidance. Preliminary Third Quarter Financial Results (unaudited) Total CHEMOSAT […]

Conference Call October 20, 8:45am EST QUEENSBURY, N.Y.–(BUSINESS WIRE)–Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomized Phase 2 clinical trial (CHOPIN Trial) presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, from Leiden University […]

Data strongly supports advancing high dose AURN001 regenerative cell therapy for patients with corneal endothelial disease to pivotal Phase 3 trial in H1 2026 SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–#AAO2025—Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12 month results from the […]

HOUSTON–(BUSINESS WIRE)–Houston’s Energy Day Festival returned for its 13th year of energy, education, excitement and engagement on Saturday, Oct. 18 at Sam Houston Park in downtown Houston. Hosted by the award-winning Consumer Energy Education Foundation (CEEF) from 11 a.m. to 3 p.m., this year’s festival built on the momentum of previous years, bringing together K-12 […]

Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology Congress 2025 With these results, KEYNOTE-B96 is the first trial of an immune checkpoint inhibitor-based treatment regimen in platinum-resistant recurrent ovarian cancer to show statistically […]

More than 92% of patients treated with AstraZeneca and Daiichi Sankyo’s ENHERTU were free of invasive disease at three years DESTINY-Breast05 presented in ESMO Presidential Symposium alongside DESTINY-Breast11 reinforce potential for ENHERTU to become a foundational treatment in curative-intent early breast cancer setting WILMINGTON, Del.–(BUSINESS WIRE)–Positive results from the DESTINY-Breast05 Phase III trial showed ENHERTU® […]

First and only systemic regimen to demonstrate durable survival benefit in this patient population KEYNOTE-905 marks the fifth study of a KEYTRUDA-based regimen in an earlier stage of cancer to demonstrate an overall survival benefit Results from the Phase 3 KEYNOTE-905 trial were selected for an official Press Briefing and will be presented during a […]

NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Snap Inc. (NYSE: SNAP) between April 29, 2025 and August 5, 2025, both dates inclusive (the “Class Period”). Snap is a technology company best known for Snapchat. For more […]

SAN JOSE, Calif.–(BUSINESS WIRE)–#agenticAI—Infrrd, a global leader in AI-driven document processing solutions, has announced the official launch of Ally, the company’s pioneering Agentic AI workforce built exclusively for the mortgage industry. The product will be formally introduced during the live webinar “AI That Audits Every Loan Before You Even Log In” on October 29, 2025, […]

New white paper outlines trauma-informed teaching strategies that support student well-being, faculty wellness and course completion for working adult learners PHOENIX–(BUSINESS WIRE)–University of Phoenix College of Social and Behavioral Sciences announces a new white paper, “Trauma-Informed Education – A Pathway for Relief, Retention, and Renewal,” authored by College leadership Sheila Babendir, Ed.D., LPAC; Barbara Burt, […]